In the absence of RCT directly comparing to nonsteroidal and selective mineralocorticoid receptor antagonists, SGLT2i and GLP-1 RA, this network meta-analysis evaluated the relative efficacy of three drugs on cardiovascular and renal outcomes in patients with T2DM and CKD. The gene discussed is NR3C2; the disease is type 2 diabetes mellitus.